DGAP-News
269
0 Kommentare
Biotest AG: Biotest opens new plasma collection centre in Brookings, South Dakota, USA
269 
0 KommentareDGAP-News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest opens new plasma collection centre in Brookings, South
Dakota, USA
24.05.2016 / 09:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biotest AG: Biotest opens new plasma collection centre in Brookings, South
Dakota, USA
24.05.2016 / 09:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
/
PRESS RELEASE
Biotest opens new plasma collection centre in Brookings, South Dakota, USA
- 12 plasma collection centres in Europe
- 19 in the US to ensure long-term plasma supply
Dreieich, 24 May 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA
(BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of
plasma proteins and biological products, is pleased to announce the
addition of its newest plasma collection centre located at Brookings, South
Dakota, USA. The state-of-the-art facility officially opened its doors for
business on May 24, 2016 and brings the total number of BPC's plasma
collection centres to 19.
"This facility is one of the four plasma centres BPC plans to open in 2016,
reinforcing our continued commitment to the expansion of our existing
network of plasma collection centres. We are fully committed to better
serve the thousands of patients worldwide who rely on plasma-based
therapies", said Ileana Carlisle, BPC's Chief Executive Officer.
BPC has invested approximately EUR1.8 million in the construction of this
facility. The Company expects to add over 40 jobs to the Brookings local
economy and currently has employment opportunities available for medical
personnel and phlebotomists.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived
products, which are used to treat various illnesses of the immune system,
the blood system, as well as in emergency medicine. Biotest is one of the
world's six largest manufacturers of plasma protein products.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,300
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
24.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg,
Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------------
465943 24.05.2016
PRESS RELEASE
Biotest opens new plasma collection centre in Brookings, South Dakota, USA
- 12 plasma collection centres in Europe
- 19 in the US to ensure long-term plasma supply
Dreieich, 24 May 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA
(BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of
plasma proteins and biological products, is pleased to announce the
addition of its newest plasma collection centre located at Brookings, South
Dakota, USA. The state-of-the-art facility officially opened its doors for
business on May 24, 2016 and brings the total number of BPC's plasma
collection centres to 19.
"This facility is one of the four plasma centres BPC plans to open in 2016,
reinforcing our continued commitment to the expansion of our existing
network of plasma collection centres. We are fully committed to better
serve the thousands of patients worldwide who rely on plasma-based
therapies", said Ileana Carlisle, BPC's Chief Executive Officer.
BPC has invested approximately EUR1.8 million in the construction of this
facility. The Company expects to add over 40 jobs to the Brookings local
economy and currently has employment opportunities available for medical
personnel and phlebotomists.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived
products, which are used to treat various illnesses of the immune system,
the blood system, as well as in emergency medicine. Biotest is one of the
world's six largest manufacturers of plasma protein products.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,300
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
24.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg,
Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------------
465943 24.05.2016
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Artikel zu den Werten
Auch bei Lesern beliebt
